Jerome H Jaffe
Overview
Explore the profile of Jerome H Jaffe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
1037
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Schwartz R, Kelly S, Mitchell S, OGrady K, Duren T, Sharma A, et al.
Drug Alcohol Depend
. 2020 Nov;
218:108392.
PMID: 33187759
Background: We report on the 24-month post-release outcomes of arrestees with opioid use disorder (OUD) enrolled in a randomized trial comparing three treatment approaches initiated in jail. Methods: Adults (N...
3.
Gryczynski J, Nordeck C, Martin R, Welsh C, Schwartz R, Mitchell S, et al.
Drug Alcohol Depend
. 2020 May;
212:107992.
PMID: 32388492
Background: Substance use disorders are associated with inefficient and fragmented use of healthcare services. The Chesapeake Regional Information System for Our Patients, Inc. (CRISP) is a Health Information Exchange (HIE)...
4.
Kelly S, Schwartz R, OGrady K, Mitchell S, Duren T, Sharma A, et al.
J Subst Abuse Treat
. 2020 May;
113:108006.
PMID: 32359668
Background: There are limited data from randomized trials about the impact of starting methadone treatment in jail on subsequent arrest after release for adults with opioid use disorder (OUD). Methods:...
5.
Schwartz R, Kelly S, Mitchell S, Gryczynski J, OGrady K, Jaffe J
J Subst Abuse Treat
. 2018 Dec;
97:7-13.
PMID: 30577902
The extent to which patient characteristics differ between individuals entering methadone treatment through community programs and jail-based programs is not known. Such differences could impact the likelihood of relapse and...
6.
Schwartz R, Mitchell M, OGrady K, Kelly S, Gryczynski J, Mitchell S, et al.
Int Rev Psychiatry
. 2018 Dec;
30(5):117-135.
PMID: 30522370
Pharmacotherapy for opioid addiction with methadone, buprenorphine, and naltrexone has proven efficacy in reducing illicit opioid use. These treatments are under-utilized among opioid-addicted individuals on parole, probation, or in drug...
7.
Treatment outcomes among a cohort of African American buprenorphine patients: Follow-up at 12 months
Monico L, Gryczynski J, Schwartz R, Jaffe J, OGrady K, Mitchell S
Am J Drug Alcohol Abuse
. 2018 May;
44(6):604-610.
PMID: 29718715
Background: Although buprenorphine/naloxone (bup/nal) is well-established as a safe and effective treatment for opioid use disorders (OUDs), there are few studies reporting 12-month outcomes of patients receiving bup/nal in formerly...
8.
Mitchell S, Monico L, Lertch E, Kelly S, Gryczynski J, Jaffe J, et al.
J Behav Health Serv Res
. 2018 Mar;
45(3):506-515.
PMID: 29536342
Clinical Trial Registration: Clinicaltrials.gov NCT 01442493.
9.
Schwartz R, Kelly S, Mitchell S, Gryczynski J, OGrady K, Jaffe J
Drug Alcohol Depend
. 2017 Sep;
180:385-390.
PMID: 28961545
This is an analysis of the odds of arrest, severity of charges, and factors predicting these outcomes in the year after methadone treatment entry using arrest records of patients (N=289)...
10.
Smith S, Jones J, Katz N, Roland C, Setnik B, Trudeau J, et al.
J Pain
. 2017 May;
18(11):1287-1294.
PMID: 28479207
Perspective: Identifying a medication's abuse potential requires assessing inappropriate medication use events in clinical trials on the basis of a standardized event classification system. The strengths and limitations of the...